Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Income from Non-Controlling Interests (2022 - 2024)

Historic Income from Non-Controlling Interests for Zentalis Pharmaceuticals (ZNTL) over the last 3 years, with Q1 2024 value amounting to -$28000.0.

  • Zentalis Pharmaceuticals' Income from Non-Controlling Interests rose 3488.37% to -$28000.0 in Q1 2024 from the same period last year, while for Dec 2024 it was -$28000.0, marking a year-over-year increase of 7543.86%. This contributed to the annual value of -$28000.0 for FY2024, which is 7543.86% up from last year.
  • As of Q1 2024, Zentalis Pharmaceuticals' Income from Non-Controlling Interests stood at -$28000.0, which was up 3488.37% from -$22000.0 recorded in Q4 2023.
  • Over the past 5 years, Zentalis Pharmaceuticals' Income from Non-Controlling Interests peaked at -$12000.0 during Q3 2023, and registered a low of -$160000.0 during Q1 2022.
  • Over the past 3 years, Zentalis Pharmaceuticals' median Income from Non-Controlling Interests value was -$35000.0 (recorded in 2022), while the average stood at -$49888.9.
  • Examining YoY changes over the last 5 years, Zentalis Pharmaceuticals' Income from Non-Controlling Interests showed a top increase of 8787.88% in 2023 and a maximum decrease of 6923.08% in 2023.
  • Quarter analysis of 3 years shows Zentalis Pharmaceuticals' Income from Non-Controlling Interests stood at -$13000.0 in 2022, then crashed by 69.23% to -$22000.0 in 2023, then fell by 27.27% to -$28000.0 in 2024.
  • Its last three reported values are -$28000.0 in Q1 2024, -$22000.0 for Q4 2023, and -$12000.0 during Q3 2023.